問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

List

2272Cases

2016-09-01 - 2020-11-09

Phase II

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY.

  • Condition/Disease

    HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

  • Test Drug

    KADCYLA

Participate Sites
10Sites

Terminated8Sites

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2015-04-10 - 2019-06-30

Phase III

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (AntiPD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA

  • Condition/Disease

    UNTREATED ADVANCED RENAL CELL CARCINOMA

  • Test Drug

    Atezolizumab

Participate Sites
3Sites

Terminated3Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of General Surgery

2014-04-01 - 2018-12-19

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2004-12-01 - 2008-01-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-02-08 - 2023-07-20

Phase III

A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease

  • Condition/Disease

    ER (+), HER2 (-) breast cancer

  • Test Drug

    SAR439859

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2018-12-18 - 2021-12-31

Phase III

A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Efpeglenatide

Participate Sites
6Sites

Not yet recruiting6Sites

2013-09-01 - 2014-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2013-06-01 - 2016-06-02

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2013-03-01 - 2015-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2017-04-01 - 2021-12-31

Phase III

A phase 3 randomized, open-label, multicenter study comparing isatuximab in combination with pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple

  • Condition/Disease

    multiple myeloma

  • Test Drug

    Isatuximab

Participate Sites
5Sites

Terminated4Sites

1 125 126 127 128 129 228
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB